+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vaginitis Therapeutics Market - Global Forecast 2026-2032- Product Image
Vaginitis Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Vaginitis Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888952
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Vaginitis Therapeutics Market is projected to reach USD 3.26 Billion in 2026. It is expected to continue growing at a CAGR of 9.55%, reaching USD 5.69 Billion by 2032.

Vaginitis therapeutics address a high-burden set of lower genital tract conditions, led by bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis. The clinical need is substantial: the CDC identifies bacterial vaginosis as the most common vaginal condition among women of reproductive age, while vulvovaginal candidiasis is estimated to affect about 75% of women at least once in their lifetime and 40%-45% more than once.

Demand for vaginitis treatment is shaped by recurrent disease, antimicrobial resistance concerns, pregnancy-related risk management, and a shift toward precise diagnosis before treatment. As payers and clinicians prioritize guideline-based care, the strongest opportunities are in rapid vaginitis diagnostics, targeted antimicrobials, antifungals for recurrent vulvovaginal candidiasis, microbiome-restoring approaches, and therapies that improve adherence through shorter and more tolerable regimens.

Transformative Shifts in the Vaginitis Treatment Landscape

The vaginitis therapeutics landscape is moving away from empiric treatment alone and toward test-guided care. Molecular panels, point-of-care tests, and improved microscopy workflows are helping distinguish bacterial vaginosis, Candida species, mixed infections, and trichomoniasis, reducing inappropriate use of antibiotics and antifungals.

Therapeutic innovation is also accelerating in recurrent and difficult-to-treat disease. FDA approvals such as secnidazole for bacterial vaginosis and trichomoniasis, ibrexafungerp for vulvovaginal candidiasis, and oteseconazole for recurrent vulvovaginal candidiasis demonstrate a clear industry shift toward differentiated mechanisms, convenient dosing, and outcomes beyond short-term symptom relief.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across vaginitis therapeutics by improving diagnostic interpretation, clinical trial design, real-world evidence generation, and pharmacovigilance. AI-enabled image analysis and decision-support tools can support more consistent interpretation of microscopy, vaginal pH, amine testing, nucleic acid amplification results, and symptom patterns when validated against clinical standards.

In drug development, machine learning can identify patient subgroups with recurrent bacterial vaginosis or recurrent vulvovaginal candidiasis, model treatment response, and detect safety signals from post-marketing datasets. The highest-value use cases will be those that are clinically validated, transparent, privacy-compliant, and integrated into clinician workflows rather than positioned as standalone replacements for laboratory confirmation.

Key Regional Insights

North America remains a high-value region for vaginitis therapeutics because of strong diagnostic adoption, favorable specialist access, and the role of CDC and FDA guidance in standardizing treatment. The United States drives innovation through prescription therapies, molecular diagnostics, and real-world evidence programs, while Canada benefits from organized primary care, public health pathways, and evidence-based women’s health services.

Europe is shaped by national reimbursement systems, antimicrobial stewardship priorities, and strong use of evidence-based gynecology guidelines across the European Union and the United Kingdom. Asia-Pacific is expanding as China, India, Japan, South Korea, Australia, and ASEAN markets increase access to women’s health services, rapid diagnostics, telehealth-enabled consultation, and branded antifungal and antibacterial therapies.

Latin America, the Middle East, and Africa show rising need but uneven access to laboratory-confirmed diagnosis and specialist care. Brazil and Mexico are important Latin American markets due to large patient populations and expanding private healthcare, while GCC countries in the Middle East invest in women’s health infrastructure and laboratory modernization. Across Africa, diagnosis and treatment access remain constrained in many settings, creating opportunities for affordable point-of-care testing, improved syndromic management, provider training, and public-private health programs.

Key Group Insights

The European Union and G7 markets set a high bar for clinical evidence, pharmacovigilance, antimicrobial stewardship, and reimbursement justification in vaginitis therapeutics. These groups are attractive for advanced antifungals, novel antibacterial regimens, microbiome-supportive approaches, and diagnostics that demonstrate clinical utility by reducing repeat visits, recurrence, and inappropriate prescribing.

BRICS countries represent significant access and volume opportunity because of large reproductive-age populations, improving healthcare coverage, and expanding domestic pharmaceutical manufacturing. China, India, Brazil, Russia, and South Africa have distinct regulatory, procurement, and pricing environments, but all offer potential for accessible generics, branded differentiated therapies, scalable diagnostics, and care models that address recurrent bacterial vaginosis and recurrent vulvovaginal candidiasis.

ASEAN and GCC markets are increasingly important for regional expansion in vaginitis treatment. ASEAN demand is supported by urbanization, private healthcare growth, pharmacy access, and rising awareness of women’s health, while GCC countries benefit from higher per-capita healthcare spending, modernization of laboratory networks, and investment in specialty care. NATO membership is less directly tied to vaginitis care, but many NATO countries overlap with high-income markets where supply resilience, regulatory harmonization, quality standards, and healthcare security influence procurement and access.

Key Country Insights

The United States is a leading commercial environment for vaginitis therapeutics, supported by CDC treatment guidelines, FDA-approved innovations, and broad use of prescription antifungals, nitroimidazoles, and diagnostic testing. Canada follows similar evidence-based care pathways, while Mexico and Brazil combine high unmet need with growing private-sector demand, pharmacy access, and broader availability of branded and generic therapies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain emphasize guideline-driven care, antimicrobial stewardship, and reimbursement evidence. Germany and France are particularly important for health technology assessment and prescription access, while the United Kingdom’s NHS framework prioritizes cost-effective diagnosis and treatment. Russia remains a sizeable market with local regulatory, pricing, and supply-chain considerations that affect access to antifungal and antibacterial therapies.

Asia-Pacific demand is led by China and India because of population scale, expanding gynecology access, increasing diagnostic adoption, and rising awareness of recurrent vaginitis. Japan, South Korea, and Australia are more mature, quality-focused markets where differentiated safety, convenience, recurrence prevention, and validated clinical evidence can support premium positioning. Across all countries, the greatest opportunity lies in pairing accurate diagnosis with therapies that reduce recurrence, improve adherence, and support antimicrobial stewardship.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based differentiation in recurrent vaginitis, mixed infections, pregnancy-sensitive care, non-albicans Candida infections, and antimicrobial stewardship. Products that demonstrate durable symptom resolution, reduced recurrence, improved tolerability, convenient dosing, and clear diagnostic fit will be better positioned with clinicians, payers, pharmacists, and patients.

Organizations should invest in companion or complementary diagnostics, real-world evidence, patient education, and adherence support that improve accurate treatment selection. Strategic partnerships with gynecology networks, diagnostic laboratories, telehealth platforms, pharmacies, and public health organizations can expand access while improving follow-up in recurrent bacterial vaginosis, recurrent vulvovaginal candidiasis, and trichomoniasis treatment pathways.

Research Methodology

This executive summary is based on a structured review of publicly available clinical guidelines, regulatory information, epidemiology sources, and peer-reviewed literature relevant to bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis, diagnostics, and treatment pathways. Core reference points include CDC sexually transmitted infection treatment guidelines, FDA drug approval information, WHO women’s health priorities, and published clinical data on prevalence, recurrence, and therapeutic outcomes.

Insights were synthesized through market segmentation by region, country, therapy class, diagnostic adoption, care setting, and policy environment. The analysis emphasizes verified, data-backed findings and excludes unsupported claims, speculative market sizing, market share, forecasting, and unvalidated clinical performance statements.

Conclusion

Vaginitis therapeutics are entering a more precise and innovation-driven phase as clinicians seek better diagnosis, improved adherence, and stronger recurrence prevention. Bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis remain common, frequently underdiagnosed, and often recurrent, creating sustained demand for therapies that combine clinical efficacy with patient-centered convenience.

Future progress will favor organizations that align therapeutics with diagnostics, antimicrobial stewardship, real-world evidence, and regional access strategies. The most competitive approaches will be those able to deliver validated, scalable, and affordable solutions across mature healthcare systems and emerging economies with significant women’s health needs.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Vaginitis Therapeutics Market, by Treatment Type
7.1. Introduction
7.2. Antifungal Treatments
7.2.1. Azoles
7.2.1.1. Clotrimazole
7.2.1.2. Fluconazole
7.2.1.3. Miconazole
7.2.2. Polyenes
7.2.2.1. Amphotericin B
7.2.2.2. Nystatin
7.3. Probiotic Treatments
8. Vaginitis Therapeutics Market, by Product Type
8.1. Introduction
8.2. Over The Counter
8.3. Prescription
9. Vaginitis Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Intravaginal
9.2.1. Creams
9.2.2. Gels
9.2.3. Suppositories
9.3. Oral
9.3.1. Capsules
9.3.2. Tablets
9.4. Topical
9.4.1. Creams
9.4.2. Gels
9.4.3. Ointments
10. Vaginitis Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Vaginitis Therapeutics Market, by End User Demographics
11.1. Introduction
11.2. Post-Menopausal Women
11.3. Pre-Menopausal Women
11.4. Pregnant Women
12. Vaginitis Therapeutics Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Vaginitis Therapeutics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Vaginitis Therapeutics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Bayer AG
16.2. bbVie Inc.
16.3. Cipla Limited
16.4. Daré Bioscience, Inc.
16.5. Dr. Reddy's Laboratories Limited
16.6. Lupin Pharmaceuticals, Inc.
16.7. Mission Pharmacal Company
16.8. Perrigo Company plc
16.9. Pfizer Inc.
16.10. Sanofi
16.11. Starpharma Holdings Limited
16.12. Sun Pharmaceutical Industries Limited
16.13. TenNor Therapeutics Limited
16.14. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL VAGINITIS THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL VAGINITIS THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL VAGINITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIFUNGAL TREATMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIFUNGAL TREATMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIFUNGAL TREATMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL AZOLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL AZOLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL AZOLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CLOTRIMAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CLOTRIMAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CLOTRIMAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL FLUCONAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL FLUCONAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL FLUCONAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL MICONAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL MICONAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL MICONAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL POLYENES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL POLYENES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL POLYENES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL AMPHOTERICIN B MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL AMPHOTERICIN B MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL AMPHOTERICIN B MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL NYSTATIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL NYSTATIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL NYSTATIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PROBIOTIC TREATMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PROBIOTIC TREATMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PROBIOTIC TREATMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL OVER THE COUNTER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL OVER THE COUNTER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL OVER THE COUNTER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL PRESCRIPTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL PRESCRIPTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PRESCRIPTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INTRAVAGINAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INTRAVAGINAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INTRAVAGINAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CREAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL GELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL GELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SUPPOSITORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SUPPOSITORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SUPPOSITORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CREAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL GELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL GELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL OINTMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL OINTMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL OINTMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL POST-MENOPAUSAL WOMEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL POST-MENOPAUSAL WOMEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL POST-MENOPAUSAL WOMEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL PRE-MENOPAUSAL WOMEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL PRE-MENOPAUSAL WOMEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL PRE-MENOPAUSAL WOMEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL PREGNANT WOMEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL PREGNANT WOMEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PREGNANT WOMEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 126. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 128. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 129. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 130. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 131. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 132. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 133. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 134. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 135. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 136. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 137. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 150. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 152. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 153. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 154. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 155. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 156. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 157. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 158. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 159. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 160. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 161. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 165. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 166. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 167. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 168. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 169. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 170. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 171. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 172. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 173. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 174. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 175. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 176. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 177. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 178. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 179. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 180. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 181. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 182. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 183. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 184. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 185. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 186. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 199. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 200. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 201. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 202. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 203. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 204. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 205. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 206. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 207. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 208. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 209. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 210. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 211. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 212. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 213. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 214. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 215. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 216. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 217. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 219. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 220. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 221. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 222. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 223. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 224. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 225. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 226. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 227. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 228. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 229. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 230. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 231. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 232. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 233. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 234. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 235. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 246. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 247. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 248. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 249. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 250. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 251. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 252. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 253. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 254. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 255. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 256. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 257. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 258. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 259. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 260. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 261. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 262. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 263. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 264. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 265. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 266. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 267. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 268. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 269. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 270. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 271. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 272. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 273. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 274. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 275. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 276. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 277. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 278. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 279. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 280. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 281. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 282. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 283. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 292. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 293. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 294. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 295. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 296. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 297. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 298. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 299. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 300. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 301. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 302. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 303. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 304. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 305. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 306. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 307. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 308. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 309. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 310. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 311. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 312. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 313. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 314. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 315. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 316. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 317. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 318. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 319. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 320. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 321. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 322. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 323. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 324. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 325. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 326. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 327. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 328. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 329. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 330. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 331. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 332. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 333. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 334. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 335. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 336. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 337. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 338. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 339. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 340. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 341. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 342. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 343. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 344. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 345. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 346. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 347. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 348. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 349. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 350. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 351. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2017-2032 (USD MILLION)
TABLE 352. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 353. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 354. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 355. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 356. CHINA VAGINITIS THERAPEUTICS MARKET SIZ

Companies Mentioned

  • Bayer AG
  • bbVie Inc.
  • Cipla Limited
  • Daré Bioscience, Inc.
  • Dr. Reddy's Laboratories Limited
  • Lupin Pharmaceuticals, Inc.
  • Mission Pharmacal Company
  • Perrigo Company plc
  • Pfizer Inc.
  • Sanofi
  • Starpharma Holdings Limited
  • Sun Pharmaceutical Industries Limited
  • TenNor Therapeutics Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.26 Billion
Forecasted Market Value ( USD ) by 2032 $ 5.69 Billion
Compound Annual Growth Rate9.5%
Regions CoveredGlobal
No. of Companies Mentioned14

Related Topics

Related Reports

Vaginitis Therapeutics - Global Strategic Business Report - Product Image

Vaginitis Therapeutics - Global Strategic Business Report

  • Report
  • 276 Pages
  • Global
From
Vaginitis Therapeutics Market Report 2026 - Product Image

Vaginitis Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Atrophic Vaginitis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035 - Product Image

Atrophic Vaginitis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

  • Report
  • 90 Pages
  • Global
From
Atrophic Vaginitis Treatment Market Outlook 2026-2034: Market Share and Growth Analysis - Product Image

Atrophic Vaginitis Treatment Market Outlook 2026-2034: Market Share and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market Report 2026 - Product Image

Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Market

Vaginitis Drug is a type of drug used to treat vaginitis, a condition characterized by inflammation of the vagina. Vaginitis is caused by a variety of factors, including bacterial, fungal, and viral infections, as well as hormonal imbalances. Vaginitis Drugs are used to treat the symptoms of vaginitis, such as itching, burning, and discharge. They may also be used to treat the underlying cause of the condition. Vaginitis Drugs are part of the larger Sexual and Reproductive Health Drugs market, which includes drugs used to treat a variety of conditions related to sexual and reproductive health, such as contraception, infertility, and sexually transmitted infections. Some companies in the Vaginitis Drug market include Pfizer, Merck, GlaxoSmithKline, Bayer, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.